CD38 and pneumonia: These results are also favorable when compared with the rates of grade 3–4 infections reported for the combinations of anti-CD38 mAbs and Pd (23% in the APOLLO study10 and 22.8% respiratory infections and pneumonia in the ICARIA study21).